Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GLPG logo GLPG
Upturn stock ratingUpturn stock rating
GLPG logo

Galapagos NV ADR (GLPG)

Upturn stock ratingUpturn stock rating
$27.99
Last Close (24-hour delay)
Profit since last BUY3.97%
upturn advisory
Consider higher Upturn Star rating
BUY since 43 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: GLPG (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $29.01

1 Year Target Price $29.01

Analysts Price Target For last 52 week
$29.01Target price
Low$22.36
Current$27.99
high$31.23

Analysis of Past Performance

Type Stock
Historic Profit -32.45%
Avg. Invested days 31
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.85B USD
Price to earnings Ratio -
1Y Target Price 29.01
Price to earnings Ratio -
1Y Target Price 29.01
Volume (30-day avg) 6
Beta -0.01
52 Weeks Range 22.36 - 31.23
Updated Date 06/30/2025
52 Weeks Range 22.36 - 31.23
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.19

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -58.83%
Operating Margin (TTM) -211.68%

Management Effectiveness

Return on Assets (TTM) -4.66%
Return on Equity (TTM) -6.36%

Valuation

Trailing PE -
Forward PE 166.67
Enterprise Value -1999445900
Price to Sales(TTM) 6.42
Enterprise Value -1999445900
Price to Sales(TTM) 6.42
Enterprise Value to Revenue 1.18
Enterprise Value to EBITDA -31.5
Shares Outstanding 65897100
Shares Floating 36702161
Shares Outstanding 65897100
Shares Floating 36702161
Percent Insiders -
Percent Institutions 22.24

Analyst Ratings

Rating 3
Target Price 29.01
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 4
Sell 1
Strong Sell 1
Strong Sell 1

ai summary icon Upturn AI SWOT

Galapagos NV ADR

stock logo

Company Overview

overview logo History and Background

Galapagos NV was founded in 1999 in Mechelen, Belgium. It initially focused on providing drug discovery services before transitioning to developing its own proprietary pipeline of drug candidates. A significant milestone was the approval of Jyseleca (filgotinib) for rheumatoid arthritis in Europe and Japan. Over time, Galapagos has evolved into a fully integrated biopharmaceutical company.

business area logo Core Business Areas

  • Research and Development: Focuses on discovering and developing novel therapies for diseases with high unmet medical needs.
  • Commercialization: Involves the marketing and sales of approved therapies, such as Jyseleca, in relevant markets.
  • Drug Discovery Services: Provides drug discovery services to other pharmaceutical companies, which was its original core business.

leadership logo Leadership and Structure

The leadership team consists of the CEO, Chief Scientific Officer, Chief Medical Officer, and other key executives. The company is structured with departments focused on R&D, commercial operations, finance, and corporate affairs. The CEO is Dr. Paul Stoffels.

Top Products and Market Share

overview logo Key Offerings

  • Jyseleca (filgotinib): A selective JAK1 inhibitor approved for rheumatoid arthritis and ulcerative colitis in certain markets (Europe, Japan). The market share varies by country, with competition from other JAK inhibitors like Xeljanz (tofacitinib) from Pfizer and Rinvoq (upadacitinib) from AbbVie. AbbVie and Pfizer are competitors. The total revenue from this product has been $177 million EUR in 2022.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. It is driven by innovation and the need for new therapies to address unmet medical needs.

Positioning

Galapagos is positioned as an innovative biopharmaceutical company with a focus on developing novel therapies for inflammatory diseases and other areas with high unmet need. Its competitive advantages include its proprietary drug discovery platform and its expertise in developing novel therapies. It is behind on revenue and earnings to the other larger competitors.

Total Addressable Market (TAM)

The TAM for inflammatory diseases is estimated to be in the billions of dollars annually. Galapagos aims to capture a significant portion of this market with its pipeline of drug candidates. For example, the JAK inhibitor market itself is expected to be $10+ billion. Their TAM is dependent on future successful pipeline products.

Upturn SWOT Analysis

Strengths

  • Strong R&D capabilities
  • Proprietary drug discovery platform
  • Experienced management team
  • Approved product (Jyseleca) in certain markets

Weaknesses

  • Reliance on partnered programs
  • High R&D spending
  • Geographic concentration in Europe
  • Jyseleca not approved in the US

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships and collaborations
  • Potential approval of pipeline candidates
  • Growth in emerging markets

Threats

  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Patent expirations
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • PFE
  • LLY
  • BMY

Competitive Landscape

Galapagos faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Its advantages include its innovative drug discovery platform and its focus on specific therapeutic areas. Their total revenue is much lower than these competitors.

Major Acquisitions

CellPoint Technologies

  • Year: 2007
  • Acquisition Price (USD millions): 12
  • Strategic Rationale: Expands Galapagos' capabilities in target discovery and validation.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by partnerships and the commercialization of Jyseleca. However, setbacks in clinical trials have hampered growth.

Future Projections: Future growth depends on the success of its pipeline candidates and expansion into new markets. Analyst estimates vary widely.

Recent Initiatives: Focusing pipeline efforts on immunology and other areas with a higher potential for success. Streamlining operations to reduce costs.

Summary

Galapagos NV ADR is a biopharmaceutical company with a focus on inflammatory diseases. Its strengths lie in its R&D capabilities and proprietary drug discovery platform, but its weaknesses include reliance on partnerships and high R&D spending. Opportunities exist for expansion into new therapeutic areas and strategic collaborations. Threats include regulatory hurdles and competition from larger companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Company Website
  • Publicly Available Financial Data

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Galapagos NV ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2005-05-06
CEO & Executive Director Mr. Henry Gosebruch
Sector Healthcare
Industry Biotechnology
Full time employees 704
Full time employees 704

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.